Journal of Clinical Oncology, ISSN 0732-183X, 12/2012, Volume 30, Issue 36, pp. 4515 - 4523
Purpose To evaluate the prognostic significance of the international European LeukemiaNet (ELN) guidelines for reporting genetic alterations in acute myeloid...
INTERNAL TANDEM DUPLICATION | OLDER PATIENTS | ONCOLOGY | FAVORABLE PROGNOSIS | MICRORNA-EXPRESSION SIGNATURES | ACUTE MYELOGENOUS LEUKEMIA | YOUNGER ADULTS | NPM1 MUTATIONS | GROUP-B | SINGLE CEBPA MUTATIONS | AGE 60 YEARS | Multivariate Analysis | Prognosis | Age Factors | Europe | Humans | Middle Aged | Risk Factors | Male | Treatment Outcome | Clinical Trials as Topic | Remission Induction | Young Adult | Disease-Free Survival | Adolescent | Aged, 80 and over | Cytogenetics | Adult | Female | Aged | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics | Hema4 | ORIGINAL REPORTS
INTERNAL TANDEM DUPLICATION | OLDER PATIENTS | ONCOLOGY | FAVORABLE PROGNOSIS | MICRORNA-EXPRESSION SIGNATURES | ACUTE MYELOGENOUS LEUKEMIA | YOUNGER ADULTS | NPM1 MUTATIONS | GROUP-B | SINGLE CEBPA MUTATIONS | AGE 60 YEARS | Multivariate Analysis | Prognosis | Age Factors | Europe | Humans | Middle Aged | Risk Factors | Male | Treatment Outcome | Clinical Trials as Topic | Remission Induction | Young Adult | Disease-Free Survival | Adolescent | Aged, 80 and over | Cytogenetics | Adult | Female | Aged | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - genetics | Hema4 | ORIGINAL REPORTS
Journal Article
Leukemia, ISSN 0887-6924, 11/2015, Volume 29, Issue 11, pp. 2143 - 2153
Current treatments for acute myeloid leukemia (AML) are designed to target rapidly dividing blast populations with limited success in eradicating the...
ONCOLOGY | HEMATOLOGY | MICRORNA EXPRESSION | CANCER-THERAPY | ATTENUATION | MicroRNAs - antagonists & inhibitors | Neoplastic Stem Cells - drug effects | Humans | Mice, Inbred C57BL | Leukocyte Common Antigens - antagonists & inhibitors | Leukemia, Myeloid, Acute - mortality | DNA Methylation | Animals | Mice | Nanoparticles - administration & dosage | MicroRNAs - physiology | Leukemia, Myeloid, Acute - therapy | Neoplastic Stem Cells - physiology | Leukemia, Myeloid, Acute - genetics | Nanoparticles | Chemotherapy | Research | Gene expression | Health aspects | Cancer | miR-126 | leukemia stem cell | antagomiR-126
ONCOLOGY | HEMATOLOGY | MICRORNA EXPRESSION | CANCER-THERAPY | ATTENUATION | MicroRNAs - antagonists & inhibitors | Neoplastic Stem Cells - drug effects | Humans | Mice, Inbred C57BL | Leukocyte Common Antigens - antagonists & inhibitors | Leukemia, Myeloid, Acute - mortality | DNA Methylation | Animals | Mice | Nanoparticles - administration & dosage | MicroRNAs - physiology | Leukemia, Myeloid, Acute - therapy | Neoplastic Stem Cells - physiology | Leukemia, Myeloid, Acute - genetics | Nanoparticles | Chemotherapy | Research | Gene expression | Health aspects | Cancer | miR-126 | leukemia stem cell | antagomiR-126
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 17, pp. 2086 - 2093
Purpose To evaluate the impact of miR-155 on the outcome of adults with cytogenetically normal (CN) acute myeloid leukemia (AML) in the context of other...
OLDER PATIENTS | EUROPEAN LEUKEMIANET | ONCOLOGY | DISTINCT GENE | PROGNOSTIC-SIGNIFICANCE | GROUP-B | EXPRESSION SIGNATURES | CANCER | RESISTANCE MODULATOR PSC-833 | PARTIAL TANDEM DUPLICATION | AGE 60 YEARS | Up-Regulation | Genetic Predisposition to Disease | Humans | Middle Aged | Risk Factors | Male | MicroRNAs - biosynthesis | MicroRNAs - metabolism | Treatment Outcome | Gene Expression Profiling | Young Adult | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Cytogenetics - methods | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Biomarkers, Tumor - genetics | MicroRNAs - genetics | Leukemia, Myeloid, Acute - genetics | To4 | To8 | ORIGINAL REPORTS | Hema9
OLDER PATIENTS | EUROPEAN LEUKEMIANET | ONCOLOGY | DISTINCT GENE | PROGNOSTIC-SIGNIFICANCE | GROUP-B | EXPRESSION SIGNATURES | CANCER | RESISTANCE MODULATOR PSC-833 | PARTIAL TANDEM DUPLICATION | AGE 60 YEARS | Up-Regulation | Genetic Predisposition to Disease | Humans | Middle Aged | Risk Factors | Male | MicroRNAs - biosynthesis | MicroRNAs - metabolism | Treatment Outcome | Gene Expression Profiling | Young Adult | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Cytogenetics - methods | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Biomarkers, Tumor - genetics | MicroRNAs - genetics | Leukemia, Myeloid, Acute - genetics | To4 | To8 | ORIGINAL REPORTS | Hema9
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2013, Volume 31, Issue 9, pp. 1172 - 1181
Purpose To identify a robust prognostic gene expression signature as an independent predictor of survival of patients with acute myeloid leukemia (AML) and use...
GENE-EXPRESSION SIGNATURE | ONCOLOGY | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | NORMAL CYTOGENETICS | YOUNGER ADULTS | NUCLEOPHOSMIN NPM1 | TANDEM DUPLICATION | CEBPA MUTATIONS | MICRORNA EXPRESSION | COMPLEX KARYOTYPE | Leukemia, Myeloid, Acute - mortality | Prognosis | Microarray Analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Gene Expression Profiling - methods | International Cooperation | Leukemia, Myeloid, Acute - genetics | To4 | To19 | ORIGINAL REPORTS | Hema9
GENE-EXPRESSION SIGNATURE | ONCOLOGY | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | NORMAL CYTOGENETICS | YOUNGER ADULTS | NUCLEOPHOSMIN NPM1 | TANDEM DUPLICATION | CEBPA MUTATIONS | MICRORNA EXPRESSION | COMPLEX KARYOTYPE | Leukemia, Myeloid, Acute - mortality | Prognosis | Microarray Analysis | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Gene Expression Profiling - methods | International Cooperation | Leukemia, Myeloid, Acute - genetics | To4 | To19 | ORIGINAL REPORTS | Hema9
Journal Article
JAMA, ISSN 0098-7484, 11/2004, Volume 292, Issue 19, pp. 2366 - 2371
CONTEXT Computerized reminder systems increase influenza and pneumococcal vaccination rates, but computerized standing order systems have not been previously...
ELDERLY PERSONS | SYSTEM | MORTALITY | IMMUNIZATION | MEDICINE, GENERAL & INTERNAL | COST-EFFECTIVENESS | METAANALYSIS | QUALITY | EFFICACY | HEALTH | CARE | Inpatients | Influenza Vaccines - administration & dosage | Reminder Systems | Vaccination - standards | Vaccination - utilization | Humans | Clinical Protocols | Hospitalization | Pneumococcal Vaccines - administration & dosage | Critical Pathways | Practice | Research | Pneumococcal vaccine | Physicians | Bacteria | Pneumonia | Computerized physician order entry | Vaccines | Influenza
ELDERLY PERSONS | SYSTEM | MORTALITY | IMMUNIZATION | MEDICINE, GENERAL & INTERNAL | COST-EFFECTIVENESS | METAANALYSIS | QUALITY | EFFICACY | HEALTH | CARE | Inpatients | Influenza Vaccines - administration & dosage | Reminder Systems | Vaccination - standards | Vaccination - utilization | Humans | Clinical Protocols | Hospitalization | Pneumococcal Vaccines - administration & dosage | Critical Pathways | Practice | Research | Pneumococcal vaccine | Physicians | Bacteria | Pneumonia | Computerized physician order entry | Vaccines | Influenza
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 15, pp. 1586 - 1594
Purpose Cytogenetically normal (CN) acute myeloid leukemia (AML) is the largest and most heterogeneous cytogenetic AML subgroup. For the practicing clinician,...
GENE-MUTATIONS | INTERNAL TANDEM DUPLICATION | AGED 60 YEARS | NORMAL KARYOTYPE | COMPLETE REMISSION | ONCOLOGY | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | GROUP-B | SINGLE CEBPA MUTATIONS | ELDERLY-PATIENTS | Predictive Value of Tests | Recurrence | Age Factors | Humans | Middle Aged | Male | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | CCAAT-Enhancer-Binding Proteins - genetics | Cytogenetic Analysis | Nuclear Proteins - genetics | Genetic Predisposition to Disease | Reproducibility of Results | Risk Assessment | Leukemia, Myeloid, Acute - pathology | Risk Factors | Decision Support Techniques | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Phenotype | Leukemia, Myeloid, Acute - diagnosis | Adolescent | Aged | Mutation | Germany | Leukemia, Myeloid, Acute - genetics | Hema5 | Hema3 | Hema4 | To2 | Bios4 | Bios3 | ORIGINAL REPORTS | Hema9
GENE-MUTATIONS | INTERNAL TANDEM DUPLICATION | AGED 60 YEARS | NORMAL KARYOTYPE | COMPLETE REMISSION | ONCOLOGY | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | GROUP-B | SINGLE CEBPA MUTATIONS | ELDERLY-PATIENTS | Predictive Value of Tests | Recurrence | Age Factors | Humans | Middle Aged | Male | Young Adult | fms-Like Tyrosine Kinase 3 - genetics | Time Factors | DNA Mutational Analysis | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | CCAAT-Enhancer-Binding Proteins - genetics | Cytogenetic Analysis | Nuclear Proteins - genetics | Genetic Predisposition to Disease | Reproducibility of Results | Risk Assessment | Leukemia, Myeloid, Acute - pathology | Risk Factors | Decision Support Techniques | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Phenotype | Leukemia, Myeloid, Acute - diagnosis | Adolescent | Aged | Mutation | Germany | Leukemia, Myeloid, Acute - genetics | Hema5 | Hema3 | Hema4 | To2 | Bios4 | Bios3 | ORIGINAL REPORTS | Hema9
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 18, pp. 2361 - 2362
Journal Article
01/2016, ISBN 9780438091214
Various exposures have been investigated by epidemiologic studies as risk factors for leukemia incidence, however studies focusing on and therefore findings...
Epidemiology
Epidemiology
Dissertation
Journal of Nutrition, ISSN 0022-3166, 2002, Volume 132, Issue 6, pp. 1219 - 1223
Experiments were conducted to evaluate the effects of supplemental fructose on postprandial glycemia. After overnight food deprivation, Zucker fatty fa/fa rats...
Blood glucose control | Zucker fatty fa/fa rats | Fructose | Glycemia | DIABETIC SUBJECTS | CORNSTARCH | HEALTHY-SUBJECTS | fructose | DIETARY FRUCTOSE | INSULIN | RESPONSES | NUTRITION & DIETETICS | GLYCOGEN-STORAGE-DISEASE | STARCH | glycemia | blood glucose control | ABSORPTION | GLUCOSE-TOLERANCE | Glucose Tolerance Test | Area Under Curve | Rats | Diabetes Mellitus, Type 2 - diet therapy | Diabetes Mellitus, Type 2 - metabolism | Fructose - metabolism | Polysaccharides - metabolism | Postprandial Period - physiology | Cross-Over Studies | Dose-Response Relationship, Drug | Rats, Zucker | Animals | Time Factors | Polysaccharides - administration & dosage | Blood Glucose - metabolism | Dietary Supplements | Fructose - administration & dosage | Disease Models, Animal | Nutrition | Blood sugar | Analysis | Physiological aspects | Research | Glucose tolerance tests
Blood glucose control | Zucker fatty fa/fa rats | Fructose | Glycemia | DIABETIC SUBJECTS | CORNSTARCH | HEALTHY-SUBJECTS | fructose | DIETARY FRUCTOSE | INSULIN | RESPONSES | NUTRITION & DIETETICS | GLYCOGEN-STORAGE-DISEASE | STARCH | glycemia | blood glucose control | ABSORPTION | GLUCOSE-TOLERANCE | Glucose Tolerance Test | Area Under Curve | Rats | Diabetes Mellitus, Type 2 - diet therapy | Diabetes Mellitus, Type 2 - metabolism | Fructose - metabolism | Polysaccharides - metabolism | Postprandial Period - physiology | Cross-Over Studies | Dose-Response Relationship, Drug | Rats, Zucker | Animals | Time Factors | Polysaccharides - administration & dosage | Blood Glucose - metabolism | Dietary Supplements | Fructose - administration & dosage | Disease Models, Animal | Nutrition | Blood sugar | Analysis | Physiological aspects | Research | Glucose tolerance tests
Journal Article
细胞研究:英文版, ISSN 1001-0602, 2015, Volume 25, Issue 6, pp. 707 - 725
Receptor-interacting protein kinase-3 (RIP3 or RIPK3) is an essential part of the cellular machinery that executes "programmed" or "regulated" necrosis. Here...
损耗 | 化疗药物 | 癌症 | 转录起始位点 | 程序性 | 坏死 | 基因甲基化 | 反应 | hypomethylating agents | programmed necrosis | RIP3 (RIPK3) | MLKL | chemotherapy | APOPTOSIS | NECROPTOSIS | DOMAIN-LIKE PROTEIN | DNA-DAMAGE | MIXED LINEAGE KINASE | MOLECULAR SWITCH | SIGNATURE | CELL-DEATH | CELL BIOLOGY | GENE | Necrosis - drug therapy | Cell Survival - drug effects | Humans | Necrosis - metabolism | Structure-Activity Relationship | Breast Neoplasms - drug therapy | Necrosis - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Xenograft Model Antitumor Assays | Receptor-Interacting Protein Serine-Threonine Kinases - genetics | Animals | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Mice, Nude | Female | Mice | Mice, Inbred BALB C | Necrosis - genetics | Receptor-Interacting Protein Serine-Threonine Kinases - deficiency | Tumor Cells, Cultured | DNA Methylation - drug effects | Original
损耗 | 化疗药物 | 癌症 | 转录起始位点 | 程序性 | 坏死 | 基因甲基化 | 反应 | hypomethylating agents | programmed necrosis | RIP3 (RIPK3) | MLKL | chemotherapy | APOPTOSIS | NECROPTOSIS | DOMAIN-LIKE PROTEIN | DNA-DAMAGE | MIXED LINEAGE KINASE | MOLECULAR SWITCH | SIGNATURE | CELL-DEATH | CELL BIOLOGY | GENE | Necrosis - drug therapy | Cell Survival - drug effects | Humans | Necrosis - metabolism | Structure-Activity Relationship | Breast Neoplasms - drug therapy | Necrosis - pathology | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Dose-Response Relationship, Drug | Xenograft Model Antitumor Assays | Receptor-Interacting Protein Serine-Threonine Kinases - genetics | Animals | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Mice, Nude | Female | Mice | Mice, Inbred BALB C | Necrosis - genetics | Receptor-Interacting Protein Serine-Threonine Kinases - deficiency | Tumor Cells, Cultured | DNA Methylation - drug effects | Original
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 14, pp. 2348 - 2355
Purpose To analyze the frequency and associations with prognostic markers and outcome of mutations in IDH genes encoding isocitrate dehydrogenases in adult de...
CHRONIC LYMPHOCYTIC LEUKEMIAS | NORMAL KARYOTYPE | ETS-RELATED GENE | OLDER PATIENTS | ONCOLOGY | POOR-PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | MICRORNA-EXPRESSION SIGNATURES | YOUNGER ADULTS | CEBPA MUTATIONS | PARTIAL TANDEM DUPLICATION | Recurrence | Humans | Middle Aged | Male | Gene Expression Profiling | Young Adult | Time Factors | DNA Mutational Analysis | MicroRNAs - analysis | Karyotyping | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Risk Assessment | Gene Frequency | Risk Factors | Kaplan-Meier Estimate | Genotype | Isocitrate Dehydrogenase - genetics | Treatment Outcome | Gene Expression Regulation, Leukemic | Gene Expression Regulation, Enzymologic | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | Leukemia, Myeloid, Acute - genetics | Original Reports | To19 | Hema4 | Hema9
CHRONIC LYMPHOCYTIC LEUKEMIAS | NORMAL KARYOTYPE | ETS-RELATED GENE | OLDER PATIENTS | ONCOLOGY | POOR-PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | MICRORNA-EXPRESSION SIGNATURES | YOUNGER ADULTS | CEBPA MUTATIONS | PARTIAL TANDEM DUPLICATION | Recurrence | Humans | Middle Aged | Male | Gene Expression Profiling | Young Adult | Time Factors | DNA Mutational Analysis | MicroRNAs - analysis | Karyotyping | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Risk Assessment | Gene Frequency | Risk Factors | Kaplan-Meier Estimate | Genotype | Isocitrate Dehydrogenase - genetics | Treatment Outcome | Gene Expression Regulation, Leukemic | Gene Expression Regulation, Enzymologic | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Mutation | Leukemia, Myeloid, Acute - genetics | Original Reports | To19 | Hema4 | Hema9
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 4, pp. 596 - 604
Purpose To analyze the prognostic significance of NPM1 mutations, and the associated gene- and microRNA-expression signatures in older patients with de novo,...
ADULT PATIENTS | CYTOPLASMIC NUCLEOPHOSMIN | NORMAL KARYOTYPE | INTENSIVE CHEMOTHERAPY | ETS-RELATED GENE | COMPLETE REMISSION | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | RISK MYELODYSPLASTIC SYNDROME | INTERNAL TANDEM DUPLICATIONS | ELDERLY-PATIENTS | Prognosis | Oligonucleotide Array Sequence Analysis | Humans | Middle Aged | Male | Gene Expression Profiling | fms-Like Tyrosine Kinase 3 - genetics | Karyotyping | Aged, 80 and over | Female | CCAAT-Enhancer-Binding Proteins - genetics | Nuclear Proteins - genetics | WT1 Proteins - genetics | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - pathology | Survival Rate | Treatment Outcome | Gene Expression Regulation, Leukemic | Mutation - genetics | Remission Induction | Aged | Biomarkers, Tumor - genetics | MicroRNAs - physiology | Neoplasm Staging | Leukemia, Myeloid, Acute - genetics | Dxst3 | To4 | Original Reports | Hema8 | Bios4 | Hema4
ADULT PATIENTS | CYTOPLASMIC NUCLEOPHOSMIN | NORMAL KARYOTYPE | INTENSIVE CHEMOTHERAPY | ETS-RELATED GENE | COMPLETE REMISSION | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | RISK MYELODYSPLASTIC SYNDROME | INTERNAL TANDEM DUPLICATIONS | ELDERLY-PATIENTS | Prognosis | Oligonucleotide Array Sequence Analysis | Humans | Middle Aged | Male | Gene Expression Profiling | fms-Like Tyrosine Kinase 3 - genetics | Karyotyping | Aged, 80 and over | Female | CCAAT-Enhancer-Binding Proteins - genetics | Nuclear Proteins - genetics | WT1 Proteins - genetics | Leukemia, Myeloid, Acute - therapy | Leukemia, Myeloid, Acute - pathology | Survival Rate | Treatment Outcome | Gene Expression Regulation, Leukemic | Mutation - genetics | Remission Induction | Aged | Biomarkers, Tumor - genetics | MicroRNAs - physiology | Neoplasm Staging | Leukemia, Myeloid, Acute - genetics | Dxst3 | To4 | Original Reports | Hema8 | Bios4 | Hema4
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 04/2011, Volume 29, Issue 10, pp. 1373 - 1381
Purpose To determine the frequency of TET2 mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene- and...
GENE-MUTATIONS | NUCLEOPHOSMIN | ONCOLOGY | FAVORABLE PROGNOSIS | MICRORNA-EXPRESSION SIGNATURES | ACUTE MYELOGENOUS LEUKEMIA | MYELOPROLIFERATIVE NEOPLASMS | YOUNGER ADULTS | MALIGNANCIES | NPM1 MUTATIONS | PARTIAL TANDEM DUPLICATION | United States | Humans | Middle Aged | Male | Gene Expression Profiling | Young Adult | Time Factors | DNA Mutational Analysis | MicroRNAs - analysis | Polymerase Chain Reaction | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Cytogenetic Analysis | Genetic Predisposition to Disease | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Gene Expression Regulation, Leukemic | DNA-Binding Proteins - genetics | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Mutation | Leukemia, Myeloid, Acute - classification | Leukemia, Myeloid, Acute - genetics | Original Reports | To19 | Hema4 | To2 | Hema9
GENE-MUTATIONS | NUCLEOPHOSMIN | ONCOLOGY | FAVORABLE PROGNOSIS | MICRORNA-EXPRESSION SIGNATURES | ACUTE MYELOGENOUS LEUKEMIA | MYELOPROLIFERATIVE NEOPLASMS | YOUNGER ADULTS | MALIGNANCIES | NPM1 MUTATIONS | PARTIAL TANDEM DUPLICATION | United States | Humans | Middle Aged | Male | Gene Expression Profiling | Young Adult | Time Factors | DNA Mutational Analysis | MicroRNAs - analysis | Polymerase Chain Reaction | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Cytogenetic Analysis | Genetic Predisposition to Disease | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Gene Expression Regulation, Leukemic | DNA-Binding Proteins - genetics | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Mutation | Leukemia, Myeloid, Acute - classification | Leukemia, Myeloid, Acute - genetics | Original Reports | To19 | Hema4 | To2 | Hema9
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2012, Volume 30, Issue 7, pp. 742 - 750
Purpose To determine the frequency of DNMT3A mutations, their associations with clinical and molecular characteristics and outcome, and the associated gene-and...
GENE-MUTATIONS | INTERNAL TANDEM DUPLICATION | OLDER PATIENTS | ONCOLOGY | FAVORABLE PROGNOSIS | POOR-PROGNOSIS | MICRORNA-EXPRESSION SIGNATURES | MYELOGENOUS LEUKEMIA | YOUNGER ADULTS | GROUP-B | RESISTANCE MODULATOR PSC-833 | Prognosis | Age Factors | Humans | Middle Aged | Male | Gene Expression Profiling | Young Adult | DNA (Cytosine-5-)-Methyltransferases - genetics | Leukemia, Myeloid, Acute - enzymology | Adolescent | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Mutation | Leukemia, Myeloid, Acute - genetics | Hema8 | To19 | Hema4 | ORIGINAL REPORTs | Hema9
GENE-MUTATIONS | INTERNAL TANDEM DUPLICATION | OLDER PATIENTS | ONCOLOGY | FAVORABLE PROGNOSIS | POOR-PROGNOSIS | MICRORNA-EXPRESSION SIGNATURES | MYELOGENOUS LEUKEMIA | YOUNGER ADULTS | GROUP-B | RESISTANCE MODULATOR PSC-833 | Prognosis | Age Factors | Humans | Middle Aged | Male | Gene Expression Profiling | Young Adult | DNA (Cytosine-5-)-Methyltransferases - genetics | Leukemia, Myeloid, Acute - enzymology | Adolescent | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Aged | Mutation | Leukemia, Myeloid, Acute - genetics | Hema8 | To19 | Hema4 | ORIGINAL REPORTs | Hema9
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2008, Volume 26, Issue 31, pp. 5078 - 5087
Purpose To evaluate the prognostic significance of CEBPA mutations in the context of established molecular markers in cytogenetically normal (CN) acute myeloid...
BINDING-PROTEIN-ALPHA | NORMAL KARYOTYPE | C/EBP-ALPHA | ETS-RELATED GENE | ONCOLOGY | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | IN-FRAME INSERTION | YOUNGER ADULTS | INTERNAL TANDEM DUPLICATIONS | BAALC EXPRESSION | Transcriptional Regulator ERG | Humans | Middle Aged | Male | Gene Expression Profiling | fms-Like Tyrosine Kinase 3 - genetics | Time Factors | MicroRNAs - analysis | Trans-Activators - genetics | Adult | Female | CCAAT-Enhancer-Binding Proteins - genetics | Neoplasm Proteins - genetics | Nuclear Proteins - genetics | WT1 Proteins - genetics | Leukemia, Myeloid, Acute - therapy | Risk Assessment | Histone-Lysine N-Methyltransferase | Treatment Outcome | Gene Expression Regulation, Leukemic | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Myeloid-Lymphoid Leukemia Protein - genetics | Adolescent | Biomarkers, Tumor - genetics | Mutation | Leukemia, Myeloid, Acute - genetics | Leukemia and Bone Marrow Transplantation
BINDING-PROTEIN-ALPHA | NORMAL KARYOTYPE | C/EBP-ALPHA | ETS-RELATED GENE | ONCOLOGY | FAVORABLE PROGNOSIS | ACUTE MYELOGENOUS LEUKEMIA | IN-FRAME INSERTION | YOUNGER ADULTS | INTERNAL TANDEM DUPLICATIONS | BAALC EXPRESSION | Transcriptional Regulator ERG | Humans | Middle Aged | Male | Gene Expression Profiling | fms-Like Tyrosine Kinase 3 - genetics | Time Factors | MicroRNAs - analysis | Trans-Activators - genetics | Adult | Female | CCAAT-Enhancer-Binding Proteins - genetics | Neoplasm Proteins - genetics | Nuclear Proteins - genetics | WT1 Proteins - genetics | Leukemia, Myeloid, Acute - therapy | Risk Assessment | Histone-Lysine N-Methyltransferase | Treatment Outcome | Gene Expression Regulation, Leukemic | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Myeloid-Lymphoid Leukemia Protein - genetics | Adolescent | Biomarkers, Tumor - genetics | Mutation | Leukemia, Myeloid, Acute - genetics | Leukemia and Bone Marrow Transplantation
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2012, Volume 30, Issue 25, pp. 3109 - 3118
Purpose To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute...
POINT MUTATIONS | INTERNAL TANDEM DUPLICATION | FAMILIAL PLATELET DISORDER | AML1/PEBP2-ALPHA-B GENE | PROGNOSTIC IMPACT | INCREASED FLT3 EXPRESSION | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | GROUP-B | MYELODYSPLASTIC SYNDROME | HEMATOPOIETIC STEM | Multivariate Analysis | Age Factors | Oligonucleotide Array Sequence Analysis | United States | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | MicroRNAs - metabolism | Young Adult | Time Factors | DNA Mutational Analysis | Polymerase Chain Reaction | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Cytogenetic Analysis | Genetic Predisposition to Disease | Risk Assessment | Leukemia, Myeloid, Acute - pathology | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Gene Expression Profiling - methods | Logistic Models | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Mutation | Core Binding Factor Alpha 2 Subunit - genetics | Leukemia, Myeloid, Acute - genetics | Hema8 | Hema5 | Hema3 | To19 | Bios1 | To2 | To4 | Original Reports | Bios4 | Bone1 | Hema9
POINT MUTATIONS | INTERNAL TANDEM DUPLICATION | FAMILIAL PLATELET DISORDER | AML1/PEBP2-ALPHA-B GENE | PROGNOSTIC IMPACT | INCREASED FLT3 EXPRESSION | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | GROUP-B | MYELODYSPLASTIC SYNDROME | HEMATOPOIETIC STEM | Multivariate Analysis | Age Factors | Oligonucleotide Array Sequence Analysis | United States | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | MicroRNAs - metabolism | Young Adult | Time Factors | DNA Mutational Analysis | Polymerase Chain Reaction | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Cytogenetic Analysis | Genetic Predisposition to Disease | Risk Assessment | Leukemia, Myeloid, Acute - pathology | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Gene Expression Profiling - methods | Logistic Models | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Phenotype | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Aged | Mutation | Core Binding Factor Alpha 2 Subunit - genetics | Leukemia, Myeloid, Acute - genetics | Hema8 | Hema5 | Hema3 | To19 | Bios1 | To2 | To4 | Original Reports | Bios4 | Bone1 | Hema9
Journal Article